In particular, the inhibitor of the mammalian target of rapamycin (mTOR), everolimus, is recommended by the European Neuroendocrine Tumor Society (ENETS) guidelines for progressive, G1/G2 PAN-NETs [24]. This evidence concerns the gene MTOR and polyarteritis nodosa.